Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
Completed
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT02269995
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
This surveillance's objectives are:
1. Unknown adverse reactions
2. Incidences of adverse drug reaction
3. Factors considered to have effect to safety and effectiveness
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and Tolerability as measured by Adverse Events Up to 30 days
- Secondary Outcome Measures
Name Time Method Efficacy of DC bead as assessed by embolic performance Up to 30 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the long-term safety outcomes of DC Bead in HCC patients post-marketing?
How does DC Bead compare to transarterial chemoembolization in HCC treatment efficacy?
Which biomarkers correlate with DC Bead response in hepatocellular carcinoma?
What adverse events are most common with DC Bead in HCC and how are they managed?
Are there combination therapies with DC Bead showing improved HCC outcomes in Eisai trials?